Search results for "cost-effective"

showing 10 items of 81 documents

Genomic profile of breast cancer: costeffectiveness analysis from the Spanish National Healthcare System perspective.

2014

Background: Costeffectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 …

Oncologymedicine.medical_specialtyCost effectivenessCost effectivenessCàncer de mamaBreast cancerBreast cancerMammaPrintInternal medicinemedicinePharmacology (medical)Online algorithmEspanyaGynecologyPublic healthmedicine.diagnostic_testbusiness.industryHealth PolicyEconomic analysisGeneral MedicineCost-effectiveness analysisGenomicsAnàlisi cost-beneficimedicine.diseaseSalut públicaGenòmicaSpainCohortLife expectancyAnàlisi econòmicabusinessOncotype DX
researchProduct

Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis

2019

Aim: Osimertinib improves progression-free survival in first-line EGFR mutation–positive non-small-cell lung cancer. Materials & methods: A Markov cohort model including costs, utilities and disutilities, was conducted to estimate quality-adjusted life-year (QALY) and incremental cost–effectiveness ratio when treating with osimertinib versus standard first-line tyrosine kinase inhibitors (TKIs). Results: Osimertinib presented higher QALYs (0.61) compared with standard EGFR–TKIs (0.42). Osimertinib costs were €83,258.99, in comparison with €29,209.45 for the standard EGFR–TKIs. An incremental cost–effectiveness ratio of €273,895.36/QALY was obtained for osimertinib. Conclusion: Osimerti…

Oncologymedicine.medical_specialtyLung NeoplasmsCost effectivenessCost-Benefit AnalysisAntineoplastic Agents03 medical and health scienceschemistry.chemical_compoundEgfr tki0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansOsimertinib030212 general & internal medicineLung cancerProtein Kinase Inhibitorshealth care economics and organizationsAcrylamidesAniline Compoundsbusiness.industryHealth PolicyCost-effectiveness analysismedicine.diseaseMarkov ChainsDacomitinibrespiratory tract diseasesErbB ReceptorsFirst line treatmentchemistry030220 oncology & carcinogenesisMutationQuality-Adjusted Life YearsNon small cellbusinessModels EconometricJournal of Comparative Effectiveness Research
researchProduct

Options pour une allocation coût-efficace des ressources

2006

06043; L'analyse coût-efficace de la qualité de l'éducation cherche à identifier la relation entre, d'une part, les moyens et les modes d'organisation scolaire et, d'autre part, les résultats obtenus. C'est cette relation que nous examinons dans ce chapitre, organisé en trois grandes sections. La première fixe le cadre financier général de la politique éducative et étudie la manière dont les problématiques liées à la qualité des services offerts s'y inscrivent. La deuxième s'attache de façon plus spécifique aux facteurs de l'organisation scolaire, en mettant en regard leur impact sur les acquis des élèves et leur coût et en examinant les options possibles pour leur mise en oeuvre et leur co…

Organisation scolaireEducational qualityEducation policyQualité de l'éducation[SHS.EDU]Humanities and Social Sciences/Education[SHS.EDU] Humanities and Social Sciences/EducationPolitique éducativeAnalyse coût-efficacité[ SHS.EDU ] Humanities and Social Sciences/EducationAcquis scolaire[SHS.ECO]Humanities and Social Sciences/Economics and FinanceSchool organizationAllocation des ressources[ SHS.ECO ] Humanities and Social Sciences/Economies and finances[SHS.ECO] Humanities and Social Sciences/Economics and FinanceEducational AttainmentCost-effectiveness Analysis
researchProduct

Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation

2021

Objectives: Optimized diagnostic algorithms to detect active infections are crucial to achieving HCV elimination. We evaluated the cost effectiveness and sustainability of different algorithms for HCV active infection diagnosis, in a context of a high endemic country for HCV infection. Methods: A Markov disease progression model, simulating six diagnostic algorithms in the birth cohort 1969‐1989 over a 10‐year horizon from a healthcare perspective was used. Conventionally diagnosis of active HCV infection is through detection of antibodies (HCV‐Ab) detection followed by HCV‐RNA or HCV core antigen (HCV‐Ag) confirmatory testing either on a second sample or by same sample reflex testing. The …

Pediatricsmedicine.medical_specialtyCost effectivenessCost-Benefit Analysiscost-effectiveneContext (language use)HepacivirusAntiviral AgentsLiver diseaseMedicineHumansbusinesshealth care economics and organizationsHepatologybusiness.industryscreeningDisease progressionHCV chronic infectionvirus diseasesDiagnostic algorithmshealthHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CHcv eliminationdigestive system diseasesWHO targetHcv core antigenbusinessAlgorithms
researchProduct

2019

Background Congenital Toxoplasmosis (CT) can have severe consequences. France, Austria, and Slovenia have prenatal screening programs whereas some other countries are considering universal screening to reduce congenital transmission and severity of infection in children. The efficiency of such programs is debated increasingly as seroprevalence among pregnant women and incidence of congenital toxoplasmosis show a steady decrease. In addition, uncertainty remains regarding the effectiveness of pre- and postnatal treatments. Method To identify cost-effective strategies, prenatal and neonatal screenings were compared using a decision-analytic model based on French guidelines and current knowled…

Pediatricsmedicine.medical_specialtyPregnancyMultidisciplinaryCost effectivenessbusiness.industryIncidence (epidemiology)030231 tropical medicinePrevalenceCost-effectiveness analysismedicine.diseaseToxoplasmosis3. Good health03 medical and health sciences0302 clinical medicineEpidemiologyCohortmedicine030212 general & internal medicinebusinessPLOS ONE
researchProduct

Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists

2012

Abstract Objectives Proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) present varying pharmacological efficacy in preventing stress ulcer bleeding (SUB) in intensive care units. The literature also reports disparate rates of ventilator-assisted pneumonia (VAP) as side effects of these treatments. We compared the cost-effectiveness of these two prophylactic pharmacological options. Methods We constructed a decision tree with a 60-day time horizon for patients at high risk for developing SUB, receiving either PPIs or H2RAs. For each treatment strategy, patients could be in one of three states of health: SUB, VAP, or no complication. Contemporary, clinically relevant probabilit…

Peptic Ulcermedicine.medical_specialtyMultivariate analysisDatabases FactualCost effectivenessmedicine.drug_classCost-Benefit AnalysisMEDLINEProton-pump inhibitorH2RAIntensive careInternal medicinemedicineHumanscost-effectivenessbusiness.industryHealth PolicyStress ulcerDecision TreesPublic Health Environmental and Occupational HealthProton Pump InhibitorsHealth Care CostsCost-effectiveness analysisLength of StayAnti-Ulcer Agentsmedicine.diseaseUnited StatesSurgerystress ulcer bleedingHistamine H2 AntagonistsMultivariate AnalysisGastrointestinal HemorrhagebusinessComplicationValue in Health
researchProduct

Tools for education : policy analysis

2003

03125http://www-wds.worldbank.org/servlet/WDSContentServer/WDSP/IB/2003/06/06/000094946_03052904033567/Rendered/PDF/multi0page.pdf; This hands-on, interactive guide to evaluating and revamping education policy is designed to help policymakers in low-income countries identify weakness and make the most efficient use of scarce education resources. Education specialist in the developed world will also find this guide to be an invaluable tool for analyzing priorities and arriving at cost-effective solutions. The out-growth of training workshops held at the World Bank, this book and CD-ROM present relevant policy problems and engage the user in a search for effective education-service delivery o…

Politique de l'éducationEducation policy[SHS.EDU]Humanities and Social Sciences/Education[SHS.EDU] Humanities and Social Sciences/EducationEnseignantAnalyse de coûtEvaluation du système éducatifCost analysis[ SHS.ECO ] Humanities and Social Sciences/Economies and financesAnalyse de régressionEquité[SHS.ECO] Humanities and Social Sciences/Economics and FinanceScolarisation des fillesTechnologie de l'éducationCost-effectiveness analysisGender - Gender and Education Health Monitoring and Evaluation Teaching and Learning Curriculum and Instruction Education - Primary Education Health Nutrition and PopulationComparative analysisEconomic analysisOutil statistiqueAnalyse coût-efficacitéEvaluation de l'éducation[ SHS.EDU ] Humanities and Social Sciences/EducationAnalyse économique[SHS.ECO]Humanities and Social Sciences/Economics and FinanceSalaireOrganisation pédagogiqueEducation EvaluationAnalyse comparativeFormation des enseignantsStatistical toolEducational system
researchProduct

A Bayesian cost-effectiveness analysis of a telemedicine-based strategy for the management of sleep apnoea: a multicentre randomised controlled trial

2015

Background Compliance with continuous positive airway pressure (CPAP) therapy is essential in patients with obstructive sleep apnoea (OSA), but adequate control is not always possible. This is clinically important because CPAP can reverse the morbidity and mortality associated with OSA. Telemedicine, with support provided via a web platform and video conferences, could represent a cost-effective alternative to standard care management. Aim To assess the telemedicine impact on treatment compliance, cost-effectiveness and improvement in quality of life (QoL) when compared with traditional face-to-face follow-up. Methods A randomised controlled trial was performed to compare a telemedicine-bas…

Pulmonary and Respiratory MedicineMaleTelemedicinemedicine.medical_specialtyEpidemiologymedicine.medical_treatmentCost-Benefit Analysislaw.inventionIndirect costsClinical trialsQuality of lifeRandomized controlled triallawmedicineHumansContinuous positive airway pressureProspective StudiesDisease management (health)EpidemiologiaTelecommunication in medicineSleep apnea syndromesPrimary health careSleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryDisease ManagementBayes TheoremCost-effectiveness analysisSíndromes d'apnea del sonMiddle AgedTelemedicinenervous system diseasesrespiratory tract diseasesClinical trialAtenció primàriaPhysical therapyQuality of LifePatient ComplianceFemalebusinessSleepFollow-Up StudiesTelecomunicació en medicinaAssaigs clínics
researchProduct

Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors.

2016

Aim. We conducted a cost-effectiveness analysis of seven hepatitis C virus (HCV) testing strategies in blood donors. Methods. Three of the seven strategies were based on HCV diagnosis and reporting guidelines in Mexico and four were from previous and current recommendations outlined by the CDC. The strategies that were evaluated determine antibody levels according to the signal-to-cut-off (S/CO) ratio and use reflex Immunoblot (IMB) or HCV RNA tests to confirm true positive (TP) cases of chronic HCV infection. Costs were calculated from the perspective of the Mexican Institute of Social Security (IMSS). A decision tree model was developed to estimate the expected number of true positive cas…

RNA virusesDecision AnalysisPhysiologyEconomicsCost-Benefit AnalysisSocial Scienceslcsh:MedicineBlood DonorsHepacivirusmedicine.disease_causeBiochemistryHepatitis0302 clinical medicineImmune Physiology030212 general & internal medicineChroniclcsh:SciencePathology and laboratory medicinehealth care economics and organizationsMultidisciplinaryImmune System ProteinsCost–benefit analysisHepatitis C virusLiver DiseaseCost-effectiveness analysisMedical microbiologyHepatitis CHCV AntibodyInfectious DiseasesVirusesEngineering and TechnologyBlood Banks030211 gastroenterology & hepatologyPathogensInfectionManagement EngineeringResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyHepatitis C virusImmunologyCost-Effectiveness AnalysisImmunoblottingChronic Liver Disease and CirrhosisMolecular Probe TechniquesAntibody levelResearch and Analysis MethodsMicrobiologyAntibodies03 medical and health sciencesChronic hepatitisHepatitis - CClinical ResearchInternal medicineparasitic diseasesmedicineHumansImmunoassaysMolecular Biology TechniquesSensitivity analysesMolecular BiologyMedicine and health sciencesBiology and life sciencesFlavivirusesbusiness.industryDecision Treeslcsh:RHepatitis C antibodyOrganismsViral pathogensProteinsHepatitis C ChronicHepatitis C AntibodiesHepatitis virusesEconomic AnalysisMicrobial pathogensHealth CareEmerging Infectious DiseasesCost Effectiveness ResearchHealth Care FacilitiesImmunologyImmunologic Techniqueslcsh:QbusinessDigestive Diseases
researchProduct

Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMI…

2013

Claudio Borghi,1 Ettore Ambrosioni,1 Stefano Omboni,2 Arrigo FG Cicero,1 Stefano Bacchelli,1 Daniela Degli Esposti,1 Salvatore Novo,3 Dragos Vinereanu,4 Giuseppe Ambrosio,5 Giorgio Reggiardo,6 Dario Zava7 1Unit of Internal Medicine, Policlinico S Orsola, University of Bologna, Bologna, Italy; 2Italian Institute of Telemedicine, Varese, Italy; 3Division of Cardiology, University of Palermo, Palermo, Italy; 4University and Emergency Hospital, Bucharest, Romania; 5Division of Cardiology, University of Perugia, Perugia, Italy; 6Mediservice, Milano, Italy; 7Istituto Lusofarmaco d'Italia SpA, Peschiera Borromeo, Italy Background: In SMILE-4 (the Survival of Myocardial Infarction Long-term…

Ramiprilmedicine.medical_specialtyCost effectivenessEconomics Econometrics and Finance (miscellaneous)Populationacute myocardial infarctionramiprilchemistry.chemical_compoundInternal medicinePost-hoc analysismedicinezofenoprilMyocardial infarctioneducationcost-effectivenesshealth care economics and organizationsOriginal Researchleft ventricular dysfunctioneducation.field_of_studylcsh:R5-920business.industryHealth Policylcsh:RM1-950acetylsalicylic acidmedicine.diseaseSMILE studycost effectiveness analysis (CEA)Confidence intervalZofenoprilangiotensin-converting enzyme inhibitorsClinicoEconomics and Outcomes Researchlcsh:Therapeutics. PharmacologychemistryCardiologyNumber needed to treatMedical emergencybusinesslcsh:Medicine (General)medicine.drug
researchProduct